Innovative therapeutic strategies to support elimination of river blindness
Active Project Grant Awarded Last action
- Award ID
- R01AI174587
- Recipient
-
The Washington University UEI L6NFUM28LQM5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,226,142
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date 79% complete
- Place of performance
- St. Louis, MO 63110, USA
Award details come from USAspending.gov.
Description
- Abstract
- Onchocerciasis (river blindness) is a major (vector-borne) neglected tropical disease caused by onchocerca volvulus and proposed by the world health organization for elimination of transmission (EOT) by 2030. Currently, national control programs attempt to achieve EOT with mass drug administration (MDA) of ivermectin (IVM) to individuals aged =5 years over prolonged periods. IVM is microfilaricidal (kills the microfilariae, MF). By 2013, only a 31% reduction in MF prevalence was achieved since MDA with IVM began in the early 1990's, making IT clear that EOT using IVM alone would not be reached. The 2018 approval of moxidectin (MOX) for treatment of individuals aged =12 years was a significant milestone in enhancing the prospects of achieving EOT. However, as MOX is deemed to be mainly microfilaricidal (but see below), IT will likely not be sufficient to meet EOT by 2030 in all endemic areas. Therefore, the development of new drugs and alternative treatment regimens to achieve onchocerciasis EOT is a pressing need. We propose to develop novel drugs and treatment regimens for facilitating sustained elimination of human onchocerciasis, based on our significant progress on: a) identification of filarial HIT drugs with macrofilaricidal activity and their putative targets; b) demonstration that in vitro, MOX, a candidate MDA drug and emodepside (EMO), a macrofilaricidal repurposed drug under clinical development, target the early stages of worm development and could consequently prevent or reduce the establishment of adult worms (defined as having prophylactic potential); and c) transmission dynamics modelling incorporating prophylactic regimens with IVM or MOX that has already indicated that BI-annual or quarterly MOX MDA would greatly help accelerate who's elimination goals compared to IVM. Our proposed aims build on the substantial progress we have thus far made and comprise: i) rationally designing novel macrofilaricidal drug candidates via medicinal chemistry optimization of known HIV-aspartic protease inhibitors (ritonavir, lopinavir, nelfinavir) that are active against 3 filarial species in vitro and in vivo; II) evaluating in parallel, in vivo, the prophylactic potential of MOX and EMO (selected based on promising in vitro results and known PK and PD profiles in humans), and III) evaluating innovative combination treatment approaches in vivo (using well-established filariasis animal models) as well as in silico by undertaking mathematical modelling to identify which suites of interventions would have the greatest potential to accelerate and protect onchocerciasis EOT in africa. By the end of the project, we anticipate to have developed novel macrofilaricidal drug candidates which target one or more aspartic proteases for advanced preclinical studies and to have identified pioneering treatment regimens through prophylaxis that will augment the critically needed complementary tools for developing new integrated therapeutic strategies for facilitating sustained elimination of human onchocerciasis.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $780,753 | |
| Amendment | $805,959 | |
| Amendment | $805,271 | |
| Original award | $834,159 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| The Regents Of The University Of California. San Francisco | $31,413 | |
| University Of California, San Diego | $37,920 | |
| New York Blood Center, Inc. | $316,076 | |
| New York Blood Center, Inc. | $948,228 | |
| University Of California, San Diego | $113,760 |
Quick answers
Who received award R01AI174587?
R01AI174587 was awarded to The Washington University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 11, 2023.
How much is award R01AI174587 worth?
$3,226,142 has been obligated on R01AI174587.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award